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OBJECTIVES This study was designed to determine how long nuclear myocardial perfusion imaging (MPI)
remains abnormal following transient myocardial ischemia.
BACKGROUND Acute rest MPI identifies myocardial ischemia with a high sensitivity when the radionuclide
is injected during chest pain. However, the sensitivity of this technique is uncertain when the
radionuclide is injected following the resolution of symptoms.
METHODS Forty patients undergoing successful coronary angioplasty were randomized into four equal
groups. Tc-99m sestamibi was injected intravenously during the last balloon inflation (acute
MPI) in 30 patients and then reinjected 1, 2, or 3 h later (delayed MPI). In a fourth group,
the radiopharmaceutical was injected at 15 min following balloon deflation (delayed MPI). A
final injection was performed at 24 to 48 h (late MPI) in 37 patients (93%).
RESULTS A perfusion defect was detected in all 30 acute MPI studies; in 7/10 patients (70%) injected
at 15 min; in 11/30 patients (37%) injected at 1, 2, or 3 h; and in 7/37 patients (19%) injected
at 24 to 48 h. Perfusion scores were 13.0 9.2 on acute MPI, 5.1 2.8 at 15 min (p 0.001
vs. acute MPI); 2.6  3.0 at 1, 2, and 3 h (p  0.001 vs. acute MPI); and 1.3  2.4 at 24
to 48 h (p  0.001 vs. acute MPI; p  0.03 vs. delayed MPI).
CONCLUSIONS Myocardial perfusion imaging may remain abnormal for several hours following transient
myocardial ischemia even when normal flow is restored in the epicardial coronary
artery. (J Am Coll Cardiol 2003;41:452–9) © 2003 by the American College of Cardiology
Foundation
Acute rest myocardial perfusion imaging (ARMPI) with
Tc-99m sestamibi is emerging as a useful technique in the
assessment of patients with spontaneous chest pain and a
nondiagnostic electrocardiogram (ECG). Recent studies
have shown that when the radiopharmaceutical is injected
while the patient is symptomatic, ARMPI is highly accurate
in the diagnosis of acute myocardial ischemia as the cause of
chest pain (1,2). However, in patients whose symptoms
have resolved, the utility of ARMPI is less clear. Whereas
some studies have shown that ARMPI will reveal a defect in
most patients when injected several hours after the resolu-
tion of ischemic symptoms (3), other studies have demon-
strated that ARMPI normalizes in the majority of such
patients (4).
Several factors may account for the disparity in these
studies. First, it is not always possible to establish the exact
time of onset and resolution of ischemia. Second, the extent
and severity of coronary stenoses and ischemia vary widely
among patients presenting with acute chest pain and may
vary over time in any one patient. Third, some patients have
had a myocardial infarction (MI) and, therefore, the defects
will persist.
In contrast to the acute clinical setting, during percuta-
neous coronary intervention the onset, duration, and extent
of ischemia are more precisely known. As an experimental
model, a radiopharmaceutical agent with insignificant re-
distribution, such as sestamibi (5), can be injected during
balloon occlusion, and myocardial perfusion imaging (MPI)
can be performed later. Once MPI is completed, a second
injection can be done to assess the fate of the defect after
restoration of normal coronary flow. We used this model to
determine how long MPI remains abnormal following
transient myocardial ischemia.
METHODS
Patients
Patients scheduled to undergo elective, single native vessel
balloon angioplasty or stenting were screened for study
participation. Patients were excluded if they had evidence of
a previous MI, if there was a 30% residual luminal
narrowing following angioplasty, or if normal coronary flow
by angiography with complete resolution of ischemic symp-
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toms and ECG changes did not occur after the final balloon
inflation. Patients with evidence of MI (creatine kinase
[CK] 2 the upper limit of normal) within 24 h of
angioplasty were also excluded. The hospital institutional
review board approved the study and written informed
consent was obtained from each patient.
Protocol
Angioplasty procedure. Coronary balloon angioplasty
and/or intracoronary stenting was performed using the
femoral approach according to standard techniques. Five
minutes after the last balloon inflation performed for clinical
purposes, an additional “study inflation” was performed at
the same site and was maintained for 3 min unless the
patient developed manifestations of severe ischemia, in
which case the inflation was terminated sooner. During the
final minute of the study inflation, a seven-lead ECG was
performed and the patient’s symptoms were assessed. Im-
mediately following balloon deflation, angiography was
performed in multiple projections. Angiograms were ana-
lyzed for residual percent stenosis and Thrombolysis In
Myocardial Infarction (TIMI) flow by an angiographer who
was blind to the results of MPI. At 18 to 24 h following the
angioplasty, cardiac enzymes were drawn and a 12-lead
ECG was performed.
MPI. RADIONUCLIDE INJECTION PROTOCOL. The radio-
nuclide injection protocol is outlined in Figure 1. Forty
patients were sequentially assigned to one of four time
interval groups: 15 min, 1 h, 2 h, and 3 h. Patients assigned
to the 1-h, 2-h, and 3-h groups (30 patients) were intrave-
nously injected with 10 to 15 mCi of Tc-99m sestamibi
during the study inflation. This was administered 30 s after
initiation of the 3-min inflation, allowing at least 1 min for
radionuclide circulation during balloon occlusion. This was
termed acute MPI. After image acquisition these patients
then received a second sestamibi injection of 30 to 35 mCi
at 1, 2, or 3 h following termination of the study inflation.
This was referred to as delayed MPI.
Patients in the 15-min group (10 patients) were injected
with 30 to 35 mCi of Tc-99m sestamibi at precisely 15 min
following termination of the study inflation. This was also
referred to as delayed MPI. These patients were not injected
with tracer during the study inflation. Patients in all four
groups were again injected with 30 to 35 mCi of Tc-99m
sestamibi at 24 to 48 h after the study inflation. This was
termed late MPI. Therefore, patients in the 1-, 2-, and 3-h
groups underwent three MPI studies (acute, delayed, and
late) and patients in the 15-min group underwent two
studies (delayed and late).
NUCLEAR MPI. Single photon emission computed tomogra-
phy (SPECT) imaging acquisition began within 60 min
after each sestamibi injection using an ADAC/Vertex dual-
headed SPECT camera equipped with low-energy, high-
resolution collimators. Sixty-four projections were obtained
over a 180-degree semicircular arc. Processing was per-
formed using a low-pass Butterworth filter with a frequency
cutoff of 0.60 cycles/pixel and an order of 5.0 for recon-
Abbreviations and Acronyms
ARMPI  acute rest myocardial perfusion imaging
CK  creatine kinase
ECG  electrocardiogram
MI  myocardial infarction
MPI  myocardial perfusion imaging
SPECT  single photon emission computed
tomography
TIMI  Thrombolysis In Myocardial Infarction
Figure 1. Nuclear injection protocol (details in the text). PCI  percutaneous coronary intervention.
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struction of the transaxial slices to a thickness of 6.6 mm.
No preprocessing or attenuation correction was used.
IMAGE INTERPRETATION AND SCORING. Images were in-
terpreted visually by a consensus of three experienced
nuclear cardiologists. Each study was interpreted separately
in a blinded fashion. A standard 17-segment model (6) was
used to assess perfusion using a 0 to 4 scale (0  normal
perfusion, 4  absent perfusion). A visual summed defect
score was calculated for each image. Myocardial perfusion
images were considered abnormal if the visual summed
defect score was 4, or if the score was 3 with any single
segment having a score 2.
Quantitative methods were used to assess both global and
regional sestamibi uptake. Results for global quantitation
are presented as the percent of the entire left ventricle that
had a perfusion defect and the results for regional quanti-
tation as the percent of the vascular territory that was
assigned to the target vessel that had a perfusion defect.
Quantitation was performed by an experienced technologist
using a commercially available software program (7). In this
analysis, gender-specific databases were used in the com-
parison between the patient and normal distributions. Left
ventricular regions in which perfusion intensity was 2.5
SD below the mean were classified as a defect.
Echocardiography. In order to assess ventricular wall mo-
tion, transthoracic echocardiography was performed in all
10 patients in the 15-min group. Imaging was begun
immediately following termination of the study inflation
and was completed within 15 min of balloon deflation.
Statistical Analysis
Data are presented as the mean  SD or as proportions.
Nominal variables were compared using a two-tailed Fisher
exact test if the expected frequency in any cell was 5 and
a chi-square test if the expected frequency was5. Summed
defect scores and quantitative defect extent were compared
between 2 groups using the Kruskall-Wallis test followed
by group-to-group comparisons using the Mann-Whitney
U test. Within group comparisons were made using the
Friedman test for2 within-group measurements, followed
by the Wilcoxon signed-rank test. In all cases, where
post-hoc testing was required, the Bonferroni correction
was used to correct for multiple comparisons. A p value
0.05 was considered statistically significant.
We had estimated the proportion of patients displaying
abnormal images to be 99%, 75%, 26% (4), and 20% (3) in
the acute, 15-min, 1 to 3 h, and 24 to 48 h groups,
respectively. At an alpha level of 0.05, a sample size of 10 in
each group would provide a 90% power to detect a
difference between these groups.
RESULTS
Clinical and procedural characteristics. The clinical and
procedural characteristics of the study patients are summa-
rized in Table 1. The dose of sestamibi was 11.7  1.1 mCi
for the acute MPI studies, 31.8  2.5 mCi for the delayed
MPI studies, and 30.8  2.9 mCi for the late MPI studies.
During the study inflation, 37/40 patients (93%) had
typical angina and/or an ST segment shift 1 mm that
resolved within minutes of balloon deflation. After the
procedure, all patients had a 20% residual stenosis with
normal contrast dye flow (TIMI grade 3). There were no
significant dissections and all intervention sites were well
opacified. In all patients in the 15-min group, echocardio-
graphic left ventricular wall motion was normal. At 18 to
24 h, eight patients had CK elevations that were 2 the
upper limit of normal with an abnormal CK-MB fraction
(mean 19.7, range: 9.7 to 46 IU; normal 0 to 7.5 IU).
Visual assessment of nuclear myocardial perfusion. The
results of SPECT imaging are presented in Table 2 and in
Figure 2. All 30 patients injected with sestamibi at the time
of coronary occlusion (acute MPI) had a perfusion defect in
a territory supplied by the target vessel. The mean defect
score for the acute MPI studies was 13.0  9.2 (range 4 to
38). Defect scores for the 30 patients who underwent acute
imaging improved from 13.0  9.2 on acute MPI to 2.6 
3.0 on delayed MPI (p  0.001 compared with acute MPI)
and to 1.3  2.4 on late MPI (p  0.001 compared with
acute MPI, p  0.03 compared with delayed MPI). The
mean defect score for the 15-min group on delayed MPI
was 5.1  2.8 and decreased to 1.8  2.2 on late MPI (p 
0.02). This defect score for delayed MPI in the 15-min
group was intermediate between that of the acute MPI
group (13.0  9.2) and the combined 1-, 2-, and 3-h
delayed MPI group (2.6  3.0) (acute vs. 15-min, p 
0.001; 15-min vs. 1-, 2-, 3-h delay, p  0.03).
On delayed MPI, a defect was present in 18 of the 40
patients (45%). The mean defect score for these 18 patients
was 6.3  1.4 (range 4 to 9). A defect was present in 7/10
patients in the 15-min group, 3/10 patients in the 1-h
group, 5/10 patients in the 2-h group, and 3/10 patients in
Table 1. Clinical and Procedural Characteristics of Study
Patients
15 min
Group
1 h
Group
2 h
Group
3 h
Group
Number of patients 10 10 10 10
Duration of study
inflation (min)
2.5  0.8 2.6  0.6 2.8  0.7 2.8  0.5
Total ischemic time
(min)*
10  6 10  5 7  2† 12  5
Unstable angina‡ 3 4 1 4
Stent 8 8 7 9
Stenosis pre-PCI (%) 84  7 87  9 86  6 84  11
Stenosis post-PCI (%) 7  7 8  8 8  9 6  8
Three-vessel CAD¶ 1 3 3 1
LAD PCI 2 5 3 3
Minor CK elevation 1 2 3 2
*Total duration of all balloon inflations; †p  0.05 compared to the 3-h group;
‡Braunwald classification; ¶the presence of a 50% luminal narrowing in either the
main trunk or in a1 mm side branch of any of the three main coronary arteries. The
Fisher exact test was used to compare nominal variables.
CAD  coronary artery disease; CK  creatine kinase; LAD  left anterior
descending artery; PCI  percutaneous coronary intervention.
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the 3-h group. In the 15-min group, the mean perfusion
score for the abnormal delayed images (n  7) was 6.5 
1.6 (range 4 to 9), in the 1-h group (n 3) it was 6.6  1.5
(range 5 to 8), in the 2-h group (n  5) it was 6.6  1.1
(range 5 to 8), and in the 3-h group (n 3) it was 5.3 1.5
(range 4 to 7).
Thirty-seven patients underwent late imaging at 24 to
48 h. Myocardial perfusion imaging was abnormal in seven
patients (19%). None of the seven patients with abnormal
late images had clinical, electrocardiographic, or enzymatic
evidence for MI. Among the 18 patients who had an
abnormal delayed MPI, 12 patients had normalized on late
imaging (Figs. 3 and 4) and 6 patients remained abnormal.
In the 12 patients who normalized, the mean defect score
was 6.1  1.5 on delayed imaging and decreased to 0.8 
0.9 on late imaging. In the six patients who remained
abnormal on late imaging, the mean defect score was 6.8 
0.9 on delayed imaging and was similar, 6.0  1.2, on late
imaging. Of the 22 patients whose MPI was normal on
delayed imaging, in 21 patients it remained normal on late
imaging and in one patient it had become abnormal.
Quantitative assessment of nuclear myocardial perfu-
sion. Results from the quantitative assessment of myocar-
dial perfusion correlated with those found on visual assess-
ment and are presented in Table 3. In the 30 patients
injected with sestamibi during coronary occlusion, the
extent of both regional and global defects on acute MPI
were similar between the 1-, 2-, and 3-h groups. In
comparison with acute MPI, regional and global defect
extents on delayed and on late MPI were significantly lower
within each group, although there were no significant
differences between the groups. For the combined 1-, 2-,
Table 2. Results of MPI by Visual Assessment
Group
Acute Delayed Late
n
SDS
(Range)
# Abn
(%)
SDS-Abn
(Range) N
SDS
(Range)
# Abn
(%)
SDS-Abn
(Range) n
SDS
(Range)
# Abn
(%)
SDS-Abn
(Range)
15 min — — — — 10 5.1  2.8
(0–9)
7/10
(70%)
6.5  1.6
(4–9)
9 1.8  2.2
(0–6)
2/9
(22%)
5.5  0.7
(5, 6)
1 h 10 15.4  11.4
(5–38)
10/10
(100%)
15.4  11.4
(5–38)
10 2.6  3.1
(0–8)
3/10
(30%)
6.6  1.5
(5–8)
9 1  1.7
(0–5)
1/9
(11%)
5  0
(5)
2 h 10 13.2  10.1
(4–38)
10/10
(100%)
13.2  10.1
(4–38)
10 3.3  3.5
(0–8)
5/10
(50%)
6.6  1.1
(5–8)
9 1.8  2.8
(0–8)
2/9
(22%)
6.5  2.1
(5, 8)
3 h 10 10.4  5.3
(4–21)
10/10
(100%)
10.4  5.3
(4–21)
10 1.9  2.5
(0–7)
3/10
(30%)
5.3  1.5
(4–7)
10 1.3  2.7
(0–7)
2/10
(20%)
6.5  0.7
(6, 7)
1, 2, 3 h 30 13  9.2
(4–38)
30/30
(100%)
13.0  9.2
(4–38)
30 2.6  3.0*‡
(0–8)
11/30
(37%)
6.2  1.3
(4–8)
28 1.3  2.4*†
(0–8)
5/28
(18%)
6.2  1.3
(5–8)
All 30 13  9.2
(4–38)
30/30
(100%)
13.0  9.2
(4–38)
40 3.2  3.1
(0–9)
18/40
(45%)
6.3  1.4
(4–9)
37 1.5  2.3
(0–8)
7/37
(19%)
6  1.1
(5–8)
*p  0.01 compared to acute; †p  0.03 compared to delayed; ‡p  0.03 compared to 15 min (delayed); #Abn  number of abnormal studies/number of studies; MPI 
myocardial perfusion imaging.
SDS  summed defect score; SDS-Abn  summed defect score for the abnormal studies only.
Figure 2. Decrease over time in the number of abnormal nuclear scans and the intensity of the nuclear defects. *p  0.001 vs. acute; †p  0.01 vs. acute;
‡p  0.001 vs. all delayed (15 min and 1 to 3 h); ¶p  0.01 vs. all delayed (15 min and 1 to 3 h); §p  0.03 vs. 15 min group.
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and 3-h groups, mean regional defect extent improved from
49.1  31.3% on acute MPI to 9.6  15.2% on delayed
MPI (p  0.001 compared with acute MPI) and to 1.4 
4.8% on late MPI (p  0.001 compared with acute MPI; p
 0.001 compared with delayed MPI). When global assess-
ment was performed, mean defect extent improved from
20.2 15.2% on acute MPI to 3.8 5.0% on delayed MPI
(p  0.001 compared with acute MPI) and to 1.5  3.5%
on late MPI (p  0.001 compared with acute MPI; p 
0.08 compared with delayed MPI).
Determinants of defect persistence. To identify factors
that may have been associated with an abnormal delayed
MPI, we compared patients with and without a defect on
delayed imaging (Table 4). The mean acute MPI defect
score was significantly greater in those patients with an
abnormal delayed MPI compared with those patients with a
normal delayed study on both visual and quantitative anal-
ysis. However, there was considerable overlap of acute
imaging scores between these two groups. No other factor
had a significant impact on the results.
Figure 3. Myocardial perfusion imaging in a patient who underwent angioplasty of the left anterior descending coronary artery with delayed imaging at
1 h. Acute imaging revealed a marked perfusion defect involving the anterior septum, anterior wall, and apex. Delayed imaging revealed a substantially less
intense defect in this distribution and late imaging revealed normal perfusion.
Figure 4. Myocardial perfusion imaging in a patient who underwent angioplasty of the right coronary artery with delayed imaging at 3 h. Acute imaging
revealed a marked perfusion defect involving the inferior wall and the inferior septum. Delayed imaging revealed a substantially less intense defect in this
distribution and late imaging revealed normal perfusion.
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DISCUSSION
This study demonstrates that sestamibi SPECT imaging
may remain abnormal for up to 3 h following the resolution
of transient myocardial ischemia and, in a small minority of
patients, for as long as 24 to 48 h. Although abnormal, the
defects on delayed imaging were considerably less intense
than those found when MPI was performed during balloon
inflations. Further, perfusion imaging tended to normalize
as time from the ischemic episode increased. Fifteen min
after the restoration of normal coronary flow, perfusion
imaging was abnormal in 70% of patients. Between 1 and
3 h imaging was abnormal in 37%, and at 24 to 48 h, it was
abnormal in 19% of patients. The probability of finding a
defect on delayed MPI correlated with the intensity of the
acute MPI defect. However, some patients with relatively
low acute MPI scores also had persistent abnormalities on
delayed imaging. No other variable predicted the presence
or absence of a delayed defect. The validity of the findings
by visual interpretation was supported by the quantitative
assessment, which revealed similar results.
Eighteen of the 40 patients had an abnormal MPI on
delayed study (sensitivity for detection of recent ischemia
45%). In 6 of these 18 patients imaging remained abnor-
mal at 24 to 48 h. These abnormalities on late imaging
could not be explained on the basis of MI. It is possible that
these abnormal images were due to attenuation artifact.
However, in 12 of the 18 patients with abnormal delayed
images, the MPI had normalized at 24 to 48 h, implying
that these abnormal delayed studies were not due to atten-
uation artifact and thus represented a postischemic abnor-
mality in myocyte sestamibi uptake.
Previous studies in patients with recent episodes of chest
discomfort have also demonstrated abnormal nuclear perfu-
sion studies following resolution of all clinically detectable
signs of ischemia (1,3,4,8). This phenomenon was first
noted by Wackers et al. (8), who found that 50% of patients
presenting with unstable angina had an abnormal nuclear
scan when injected with thallium within 6 h of pain
resolution. Bilodeau et al. (1) found that 65% of patients
injected 4 h following an episode of ischemic chest
discomfort had a nuclear perfusion defect. Varetto et al. (3)
demonstrated that 11 patients with documented coronary
artery disease had abnormal nuclear scans when injected
with sestamibi 2 to 8 h following the resolution of ischemic
chest discomfort, and in 9 of these patients, the perfusion
scans had normalized by 24 to 48 h. In a model similar to
ours, Gallik et al. (4) injected 35 angioplasty patients with
sestamibi during balloon occlusion and then again 2 to 3 h
postangioplasty. Similar to our findings, in that study 26%
of patients had an abnormal scan on delayed imaging. Our
study extends these observations by performing MPI at
multiple, prespecified time points and by rigorously exclud-
ing patients with prior or periprocedural infarctions.
Ambrosio et al. (9) studied this phenomenon in patients
with exercise-induced demand ischemia who developed
postischemic contractile dysfunction. Patients were injected
with sestamibi 30 min postexercise and, contrary to our
findings, all scintigrams were normal. This model differed
from our model in that the mechanism of ischemia was
different (demand vs. supply) and there was no evidence for
postischemic myocardial stunning in our patients. Together,
Table 3. Results of MPI by Quantitative Assessment
Acute MPI Delayed MPI Late MPI
n
RDE (%)
(Range)
GDE (%)
(Range) n
RDE (%)
(Range)
GDE (%)
(Range) n
RDE (%)
(Range)
GDE (%)
(Range)
15 min — — 10 11.2  17.5
(0–56.2)
4.9  5.3
(0–16.5)
9 7.6  15.7
(0–42.5)
3.2  6.5
(0–16.7)
1 h 10 55.7  32.9
(0–91.2)
24.9  16.3
(3.7–53.5)
10 13.3  15.4*
(0–38.8)
5.3  5.1*
(0–16.1)
9 3.4  7.7*
(0–22.5)
1.4  1.8*
(0–3.9)
2 h 10 54.5  29.8
(0–96.2)
20.3  13.5
(6.3–46.7)
10 10.2  18.2*
(0–57.5)
3.8  5.8*
(0–17.6)
9 0  0*
(0)
1.4  2.9*
(0–9.1)
3 h 10 37.1  30.7
(0–71.9)
15.5  15.9
(0–47.8)
10 5.4  11.8*
(0–37.8)
2.2  3.9*
(0–11.3)
10 1  3.1*
(0–10)
1.7  5.1*
(0–16.3)
1, 2, 3 h 30 49.1  31.3
(0–96.2)
20.2  15.2
(0–53.5)
30 9.6  15.2*
(0–57.5)
3.8  5.0*
(0–17.6)
28 1.4  4.8*†
(0–22.5)
1.5  3.5*‡
(0–16.3)
*p  0.001 vs. acute MPI; †p  0.001 vs delayed MPI; ‡p  0.08 compared to delayed MPI.
GDE  global defect extent (percentage of the left ventricle that had a perfusion defect); MPI  myocardial perfusion imaging; RDE  regional defect extent (percent of
the vascular territory that was assigned to the target vessel that had a perfusion defect).
Table 4. Determinates of Abnormal Delayed Imaging
No Persistent
Defect
Persistent
Defect
Number of patients 22 18
Acute MPI defect score 9.4  5.2 19.1  11.5*
Unstable angina† 5 (23%) 7 (39%)
Total ischemic time (min) 9.1  4.1 11  6
Three-vessel disease 5 (23%) 3 (17%)
LAD intervention 7 (32%) 6 (33%)
Angiographic collaterals‡ 3 (14%) 1 (5%)
Minor CK elevation 4 (18%) 4 (22%)
*p  0.05 compared to “No Persistent Defect”; †Braunwald classification; ‡collaterals
supplying the intervention artery. A Fisher exact test was used for comparisons
between groups for the following variables: ‘three-vessel CAD’, ‘angiographic collat-
erals’ and ‘minor CK elevation.’ For ‘unstable angina’ and ‘LAD intervention’ the chi
square test was used.
CK  creatine kinase; LAD  left anterior descending coronary artery; MPI 
myocardial perfusion imaging. Three-vessel disease: the presence of a 50% luminal
narrowing in either the main trunk or in a 1 mm side branch of any of the three
main coronary arteries.
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these studies suggest that the occurrence of postischemic
sestamibi defects may be influenced by the mechanism of
ischemia.
Reason for postreperfusion defects. In the earlier studies
it was assumed that the defects on delayed imaging were in
many cases due to either significant residual stenoses with
silent myocardial ischemia or to recent or remote infarction
(1,3,4,10). In the present study, patients with MI were
excluded, and therefore this could not explain our findings.
Ongoing ischemia was also unlikely, as no patient had a
significant residual stenosis, all had normal epicardial coro-
nary artery flow, and all parameters of ischemia were normal
at the time of sestamibi injection. In the 15-min group,
echocardiographic left ventricular wall motion was normal
in all 10 patients, indicating that the defects were not related
to the phenomenon of postischemic myocardial stunning.
These findings are consistent with animal models of tran-
sient ischemia where, following similar brief periods of
ischemia, myocardial function returned to normal within
several minutes (11).
One possible explanation for the delayed defects is that
there were subtle microcirculatory flow abnormalities that
were not significant enough to generate clinically apparent
ischemia or be detected angiographically, but were signifi-
cant enough to cause a sestamibi perfusion abnormality.
Relevant to this hypothesis is the study of Sinusas et al. (12).
Using a transient ischemia model they demonstrated a
decrease in subendocardial flow as measured by micro-
spheres, even when flow in the epicardial coronary artery
had returned to normal. Thus, a persistent but relatively
subtle reduction in subendocardial flow following ischemia
may explain our findings of persistent sestamibi defects.
Another possible explanation for the persistent defects
involves the impact of transient ischemia on the cellular
mechanism of sestamibi uptake. Sestamibi enters the myo-
cyte by passive diffusion in response to an electrical gradient
across the cell and mitochondrial membranes (13,14).
When this electrical potential is reduced, there is decreased
movement of sestamibi into the cytosol and mitochondria
(14). It has been demonstrated in animal models that
transient ischemia induces biochemical and ultrastructural
alterations within the myocyte that may last up to several
days (15) and that may negatively impact myocardial ener-
getics (15,16). In a clinical study, Camici et al. (17) has
shown that in the postischemic period there are changes in
the rates of myocyte glucose metabolism, implying altered
glycogen metabolism and depletion of cellular energy stores.
As a corollary to this, Kloner et al. (15) found microscopic
evidence of depleted glycogen stores in dog hearts exposed
to transient ischemia. Also in a dog model, DeBoer et al.
(16) demonstrated that transient coronary occlusion signif-
icantly decreased subendocardial adenosine triphosphate
levels, which remained depressed for up to 72 h following
reperfusion. In models of pharmacologically simulated isch-
emic injury, Piwnica-Worms et al. (18) have demonstrated
that there are metabolic derangements that cause a decrease
in the membrane potentials with a subsequent decrease in
sestamibi uptake.
Such metabolic abnormalities may be the basis for our
findings. It is possible that the defects in delayed MPI found
in the present study could be explained by a transient,
postischemic decrease in the membrane potential attribut-
able to altered myocyte energetics, ultrastructure, or metab-
olism as described in the earlier studies. If this were the case,
it would have to be assumed that such a metabolic derange-
ment would not be profound enough to cause a detectable
decrease in contractility or change in the surface ECG, but
would be significant enough to interfere with the electrical
gradient across the cell membrane. Such a scenario, a
“stunned membrane,” would be analogous to the transient
postischemic contractile dysfunction that has been well
described (19). If such a mechanism were confirmed in
future studies, it would imply that sestamibi is not a pure
bloodflow tracer and that its uptake may be influenced by
postischemic alterations in the transmembrane electro-
chemical gradient.
Clinical implications. Although this study has demon-
strated that perfusion defects may persist following brief
episodes of coronary occlusion, the clinical utility of this
finding may be limited, as the sensitivity of delayed MPI
was relatively low, with only 37% of patients having defects
at 1 to 3 h following reperfusion. Furthermore, a perfusion
abnormality on SPECT imaging after this interval likely
underestimates the extent of jeopardized myocardium.
There are, however, several important differences between
the design of this study and the clinical situation.
In this model, myocardial ischemia was induced by brief
coronary occlusion followed by complete, or almost com-
plete, elimination of the culprit narrowing with restoration
of normal epicardial flow. In contrast, in patients presenting
with angina at rest, the culprit lesion is usually a nonocclu-
sive, complex, severe narrowing that remains severely ste-
nosed even after symptoms have resolved (20–22). Myocar-
dial ischemia results from cyclic worsening of the stenosis
attributable to changes in coronary tone or thrombus size
(23), and bloodflow across the lesion may not have returned
to normal following resolution of clinically detectable isch-
emia. Therefore, it might be expected that in the clinical
setting, perfusion defects following the resolution of chest
pain would occur more often and persist for longer periods
of time than would be predicted from the results of our
study. Thus, the findings from this study may underestimate
the clinical utility of delayed MPI in patients with recently
resolved chest pain.
These findings may also have prognostic implications.
Tatum et al. (24) found that normal sestamibi imaging in
patients presenting within several hours of the onset of chest
discomfort was associated with a very low incidence of
adverse cardiac events over the ensuing 12 months. Our
finding that normal delayed imaging correlated with less
severe defects on acute imaging suggests that a smaller area
of myocardium was at ischemic risk in these patients
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compared with patients having abnormal delayed studies.
Such a smaller area of ischemic risk may provide the basis
for the findings in the Tatum et al. (24) study.
Study limitations. This study has several important limi-
tations. First, the design of the study necessitated a low-
dose/high-dose, “stress/rest” protocol. Therefore, it is pos-
sible that the delayed imaging defects were to some extent
artifactual because of inadequate “fill-in” of the acute
imaging defects. Both Heo et al. (25) and Taillefer et al.
(26) have addressed this issue, and although they found less
reversibility with a stress/rest sequence than with a rest/
stress sequence, the absolute magnitude of the difference
was small, with approximately 90% concordance between
studies. Further, it is notable that in our study, patients in
the 15-min group did not undergo acute imaging yet had
abnormal delayed imaging. This argues strongly that inad-
equate fill-in cannot entirely explain the findings.
Second, the study inflation was maintained for 30 to
150 s following the injection of sestamibi. It is known that
myocardial uptake of sestamibi occurs for up to 300 s
following intravenous injection and, therefore, it is possible
that the defect scores were underestimated.
Finally, attenuation correction was not available at the
time of this study. Therefore, attenuation artifact as a
contributor to the persistent defects cannot be excluded.
Conclusions. This study demonstrates that myocardial
perfusion imaging with Tc-99m sestamibi may remain
abnormal for at least several hours following the resolution
of transient coronary ischemia despite the absence of coro-
nary obstruction, the normalization of epicardial flow, and
the resolution of all clinical manifestations of ischemia. The
mechanistic basis for this finding is unclear; however,
previous reports raise the possibility that transient,
ischemia-induced alterations in myocyte membrane func-
tion may be a factor. These results are relevant to the use of
myocardial perfusion imaging in patients who have recently
presented with chest pain at rest.
Reprint requests and correspondence: Dr. Daniel B. Fram,
Cardiac Lab, Hartford Hospital, 80 Seymour Street, P.O. Box 5037,
Hartford, Connecticut 06102-5037. E-mail: dfram@harthosp.org.
REFERENCES
1. Bilodeau L, The´roux P, Gregoire J, Gagnon D, Arsenault A.
Technetium-99m sestamibi tomography in patients with spontaneous
chest pain: correlation with clinical, electrocardiographic and angio-
graphic findings. J Am Coll Cardiol 1991;18:1684–91.
2. Hilton TC, Thompson RC, Williams HJ, Saylors R, Fulmer H,
Stowers SA. Technetium-99m sestamibi myocardial perfusion imag-
ing in the emergency room evaluation of chest pain. J Am Coll Cardiol
1994;23:1016–22.
3. Varetto T, Cantalupi D, Altieri A, Orlandi C. Emergency room
technetium-99m sestamibi imaging to rule out acute myocardial
ischemic events in patients with nondiagnostic electrocardiograms.
J Am Coll Cardiol 1993;22:1804–8.
4. Gallik DM, Obermueller SD, Swarna US, Guidry GW, Mahmarian
JJ, Verani MS. Simultaneous assessment of myocardial perfusion and
left ventricular function during transient coronary occlusion. J Am Coll
Cardiol 1995;25:1529–38.
5. Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of
technetium-99m-hexakis-2methoxy-2-methylpropyl-isonitrile. Circu-
lation 1988;77:491–8.
6. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized
myocardial segmentation and nomenclature for tomographic imaging
of the heart. Circulation 2002;105:539–42.
7. Kritzman JN, Ficaro EP, Liu YH, Wackers FJT, Corbett JR.
Evaluation of 3D-MSPECT for quantification of Tc-99m sestamibi
defect size. J Nucl Med 1999;40:181P.
8. Wackers FJT, Lie KI, Liem KL, et al. Thallium-201 scintigraphy in
unstable angina pectoris. Circulation 1978;57:738–42.
9. Ambrosio G, Betocchi S, Pace L, et al. Prolonged impairment of
regional contractile function after resolution of exercise-induced an-
gina. Circulation 1996;94:2455–64.
10. Becker LC. Technetium99m sestamibi tomography in patients with
spontaneous chest pain. J Am Coll Cardiol 1991;18:1692–3.
11. Egeblad H, Haunso S, Amtorp O. Regional dynamic behavior of the
canine myocardium following brief ischemia: wall thickness, wall
thickening and blood flow. Cardiovasc Res 1982;16:249–55.
12. Sinusas AJ, Trautman KA, Bergin JD, et al. Quantification of area at
risk during coronary occlusion and degree of myocardial salvage after
reperfusion with technetium-99m methoxyisobutyl isonitrile. Circula-
tion 1990;82:1424–37.
13. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondria
and plasma membrane potentials on accumulation of hexakis (2-
methoxyisobutylisonitrile) technetium (I) in cultured mouse fibro-
blasts. J Nucl Med 1990;31:1646–53.
14. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of
hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick
myocardial cells. Mitochondria and plasma membrane potential de-
pendence. Circulation 1990;82:1826–38.
15. Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental
coronary artery perfusion: effects on infarct size, myocardial function,
biochemistry, ultrastructure and microvascular damage. Circulation
1983;68 Suppl I:I8–15.
16. DeBoer LWV, Ingwall JS, Kloner RA, Braunwald E. Prolonged
derangements of canine myocardial purine metabolism after brief
coronary occlusion not associated with anatomic evidence of necrosis.
Proc Natl Acad Sci USA 1980;77:5471–5.
17. Camici P, Araujo LI, Spinks T, et al. Increased uptake of 18F-
fluorodeoxyglucose in postischemic myocardium of patients with
exercise-induced angina. Circulation 1986;74:281–92.
18. Piwnica-Worms D, Chiu ML, Kronauge JF. Divergent kinetics of
201TI and 99mSESTAMIBI in cultured chick ventricular myocytes
during ATP depletion. Circulation 1992;85:1531–41.
19. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and
cellular implications of stunning, hibernation, and preconditioning.
An NHLBI workshop. Circulation 1998;97:1848–67.
20. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology
and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol
1985;5:609–16.
21. Williams AE, Freeman MR, Chisholm RJ, Patt NL, Armstrong PW.
Angiographic morphology in unstable angina pectoris. Am J Cardiol
1988;62:1024–7.
22. Dangas G, Mehran R, Wallenstein S, et al. Correlation of angio-
graphic morphology and clinical presentation in unstable angina. J Am
Coll Cardiol 1997;29:519–25.
23. The´roux P, Fuster V. Acute coronary syndromes. Unstable angina and
non–Q-wave myocardial infarction. Circulation 1998;97:1195–206.
24. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for
the evaluation and triage of the chest pain patient. Ann Emerg Med
1997;29:116–25.
25. Heo J, Kegel J, Iskandrian AS, Cave V, Iskandrian BB. Comparison of
same-day protocols using technitium-99m-sestamibi myocardial im-
aging. J Nucl Med 1992;33:186–91.
26. Taillefer R, Gagnon A, Laflamme L, Gregoire J, Leveille J, Phaneuf
D-C. Same day injections of Tc-99m methoxy isobutyl isonitrile
(hexamibi) for myocardial tomographic imaging: comparison between
rest-stress and stress-rest injection sequences. Eur J Nucl Med 1989;
15:113–7.
459JACC Vol. 41, No. 3, 2003 Fram et al.
February 5, 2003:452–9 Persistence of Sestamibi Defects
